8-K

                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT

                  PURSUANT TO SECTION 13 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): August 6, 2013

                            TECHNE CORPORATION
             (Exact Name of Registrant as Specified in Charter)


       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                614 Mckinley Place NE
                   Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))









Item 8.01  Other Events

A copy of the press release issued by Techne Corporation on August 6,
2013, announcing a cash dividend is attached hereto as Exhibit 99.1.



Item 9.01 Financial Statements and Exhibits

     (d) Exhibits

         99.1 Press Release dated August 6, 2013.








                            SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: August 6, 2013                 TECHNE CORPORATION
                                      By: /s/ Charles R. Kummeth
                                      ---------------------------
                                      Name: Charles R. Kummeth
                                      Title: Chief Executive Officer



                          EXHIBIT INDEX

    Exhibit No. Description
    ----------- -----------

    99.1 Press release of Techne Corporation dated August 6, 2013.

EX-99.1

                        TECHNE CORPORATION DECLARES DIVIDEND


Minneapolis/August 6, 20133/ -- Techne Corporation (NASDAQ:TECH) announced
that its Board of Directors has decided to pay a dividend of $0.30 per share
for the quarter ended June 30, 2013.  The quarterly dividend will be payable
August 31, 2013 to all common shareholders of record on August 16, 2013.
Future cash dividends will be considered by the Board of Directors on a
quarterly basis.



                 *  *  *  *  *  *  *  *  *  *  *  *  *  *

TECHNE Corporation and Subsidiaries (the Company) are engaged in the
development, manufacture and sale of biotechnology products and clinical
diagnostic controls. These activities are conducted through the Company's two
operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems)
of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of
Abingdon, England.

R&D Systems is a specialty manufacturer of biological products. R&D Systems
has four subsidiaries: BiosPacific, Inc. (BiosPacific), located in
Emeryville, California, Boston Biochem, Inc., located in Cambridge,
Massachusetts, Bionostics Holdings Limited (Bionostics), operating in Devens,
Massachusetts, and R&D Systems China Co. Ltd., (R&D China), located in
Shanghai, China. BiosPacific is a worldwide supplier of biologics to
manufacturers of in vitro diagnostic systems and immunodiagnostic kits.
Boston Biochem is a leading developer and manufacturer of ubiquitin-related
research products.  Bionostics is a leading supplier of control solutions
used in point of care blood glucose and blood gas testing.

R&D China and R&D Europe distribute the Company's biotechnology products. R&D
Europe has two subsidiaries: Tocris Holdings Ltd. (Tocris) of Bristol,
England and R&D Systems GmbH, a German sales operation. Tocris is a leading
supplier of chemical reagents for non-clinical life science research.

Contact:  Greg Melsen, CFO
          Kathy Backes, Controller
          (612) 379-8854